-
Pharmaceutical companies have successively disclosed their transcripts for the first three quarters. Which company has strong R&D investment?
Time of Update: 2021-11-15
While the three quarterly reports were disclosed, the research and development expenses of various pharmaceutical companies in the first three quarters have also been exposed .
According to Hengrui Pharmaceutical’s 2021 third quarter report released on October 19, Hengrui Pharmaceutical’s R&D investment continued to increase this year.
-
Financial fraud, market manipulation, and bribery of these pharmaceutical company bosses have beaten the cards in their hands.
Time of Update: 2021-11-15
Whether it is Ma Xingtian of Kangmei or Zhang Meihua of Tongjitang, whether it is Liu Qun of Tiansheng Pharmaceuticals or Liu Lingan of Hansen Pharmaceuticals, they have relied on their personal vision and courage to start their own businesses, and they have put their companies on the capital market and rewritten their lives.
-
In the next 4 years, 13,000 small and medium-sized pharmaceutical wholesale companies may face elimination
Time of Update: 2021-11-15
js?cdnversion='+~(-new Date()/36e5)]; Keywords: In the next 4 years, 13,000 small and medium-sized pharmaceutical wholesale companies may face elimination, medicine Next: Energy storage biology With the development of the pharmaceutical industry, Yantai plans to surpass 200 billion yuan in revenue from its main business in 2023.
-
To strictly control the quality and safety of drugs, pharmaceutical equipment needs to continue to exert efforts in two aspects
Time of Update: 2021-11-15
However, compared with large foreign pharmaceutical companies, the overall technical equipment level of domestic pharmaceutical companies is generally relatively low, especially in the high-end field; in addition, the dependence of drugs on people in the production process is still relatively high, which makes the drugs produced The quality also varies .
-
The new business cycle of pharmaceutical equipment is coming. Which types of enterprises can significantly benefit from the rebound in demand?
Time of Update: 2021-11-15
Analysts pointed out that in recent years, under the promotion of national policies such as encouraging new drug research and development, regularization of volume purchases, and consistency evaluation, the number of pharmaceutical products has continued to increase.
-
How useful is it to pull black and white banners in pharmaceutical companies?
Time of Update: 2021-11-15
We are an acquisition of a pharmaceutical company, and there must be professional management, but it only involves the change of equity .
If the product of a pharmaceutical company is not good, there is a high probability that no one will buy it .
-
With the acceleration of the development of the biopharmaceutical industry, pharmaceutical companies are also using innovation to help
Time of Update: 2021-11-15
It should be noted that from the current point of view, while my country's biopharmaceutical equipment is developing continuously, the lack of mid-to-high-end market is serious, the overall innovation capability of the industry is still weak, and the product quality is also uneven.
-
Anti-gout drugs are coming together, and the market for over 3 billion is about to start!
Time of Update: 2021-11-15
At present, in the face of the huge anti-gout drug market, major domestic pharmaceutical companies are deploying one after another, including the development of new anti-gout drugs through independent research and development or introduction .
-
Detailed rules for supporting traditional Chinese medicine formula particles have been issued in many places, and pharmaceutical companies will welcome new opportunities
Time of Update: 2021-11-15
In this context, manufacturers need to fulfill the main responsibility and related obligations of the whole life cycle of drugs in the future, strengthen management and control in the production and management process, and ensure the quality and safety of traditional Chinese medicine formula particles in order to better assist the industry.
-
What are the reasons behind Hillhouse's continued reduction in the CXO industry?
Time of Update: 2021-11-15
It is understood that Hillhouse Investment Fangda Holdings and held the shares for 2 years .
The transferee, Ye Xiaoping, invested in Tigermed in the form of equity; in October 2020, Hillhouse subscribed for 4,405,300 shares of Kailai Ying (with a capital of nearly 1 billion) through a fixed increase, accounting for 1.
-
Voriconazole for injection by Puli Pharmaceuticals obtains marketing approval from the Ministry of Health of Costa Rica
Time of Update: 2021-11-15
On October 31, Puli Pharmaceuticals issued an announcement stating that the company had recently received a marketing permit for 200 mg of voriconazole for injection issued by the Ministry of Health of Costa Rica .
-
Shuyu civilians: 413 stores added in 9 months
Time of Update: 2021-11-15
In the first three quarters of this year, Shuyu Civilian expanded to 413 new stores, and the number of new stores in the same period last year was 93, a year-on-year increase of 344.
-
280 pharmacies have a good harvest
Time of Update: 2021-11-15
25 million yuan, involving 12 stores, and the equity transfer procedures of the project were completed in July 2021 .
79 million yuan, involving 20 stores, the project equity delivery procedures were completed in August .
-
Tianyan Pharmaceuticals launches a clinical trial cooperation of ADG106 combined with nivolumab in the treatment of patients with non-small cell lung cancer in Singapore
Time of Update: 2021-11-15
The Phase Ib/II trial will evaluate the efficacy of this new combination therapy in advanced non-small cell lung cancer (NSCLC) patients who have progressed after previous treatment .
-
The two companies have reviewed the 1 billion gastric motility drug
Time of Update: 2021-11-15
Sales of terminal domperidone in physical pharmacies in cities in China (unit: ten thousand yuan)Source: Mi Nei. com, China's urban physical pharmacy terminal competition patternIt is worth mentioning that domperidone tablets are the TOP1 variety in the gastrointestinal antispasmodic, anticholinergic, and gastrodynamic drug market in the physical pharmacies of cities in China.
-
my country's pharmaceutical industry continues to attract attention from the international market, and license-out transactions are active
Time of Update: 2021-11-15
recently issued an announcement stating that the company and HUYABIO INTERNATIonAL (hereinafter referred to as "HUYABIO") have signed a formal agreement on "Shanghai Pharmaceuticals Licenses the Overseas Rights and Interests of SPH6162 to HUYABIO" .
-
Dapagliflozin is the first imitation of Fuyuan Pharmaceutical and Lukang Pharmaceutical to be approved at the same time
Time of Update: 2021-11-15
On October 28, the latest NMPA approval document showed that Shandong Lukang Pharmaceutical and Dapagliflozin of Beijing Fuyuan Pharmaceutical were approved for listing at the same time .
Dapagliflozin is an SGLT2 inhibitor hypoglycemic drug developed by AstraZeneca .
-
Hainan issued 14 "Drug Production Licenses" (B Certificates), injecting new vitality into the development of medicine
Time of Update: 2021-11-15
For holders of drug research and development institutions and other holders to apply for a drug production license (B certificate), the notice issued by Hainan Province this year pointed out that priority should be given to the application .
-
ADC vs PDC——Inventory of current status of ADC-PDC drug research and development at home and abroad
Time of Update: 2021-11-15
The FDA accelerated the approval of Pepaxto combined with dexamethasone for the treatment of patients with relapsed refractory multiple myeloma (RRMM), based on the results of a pivotal phase II clinical trial (HORIZON), these patients have previously received at least four previous therapies, including proteases Body inhibitors, immunomodulators, monoclonal antibodies targeting CD38 .
-
Traditional Chinese Medicine Preparation Center of Medical Institutions-the next golden track in the Chinese medicine industry
Time of Update: 2021-11-15
Based on this, the State Council in the "Notice on Several Policies and Measures to Accelerate the Development of the Characteristic of Traditional Chinese Medicine" issued in early 2021 specifically proposed that the Chinese medicine decoction pieces and preparations processed and used by medical institutions shall be self-priced, and those that meet the conditions can be included in the scope of medical insurance payment according to regulations.
